Article
Biochemistry & Molecular Biology
Maria Ansar, Yue Qu, Teodora Ivanciuc, Roberto P. Garofalo, Antonella Casola
Summary: Respiratory syncytial virus (RSV) infection causes pathogenic inflammation and oxidative injury. RSV impairs antioxidant responses by degrading NRF2, a transcription factor that controls the expression of antioxidant enzymes. Lack of type I interferon receptor can reduce RSV-induced clinical disease and airway inflammation, and restore NRF2 levels and airway antioxidant capacity.
Review
Medicine, Research & Experimental
Sofia Tejada, Raquel Martinez-Reviejo, Hanife N. Karakoc, Yolanda Pena-Lopez, Oriol Manuel, Jordi Rello
Summary: This study summarized the efficacy and safety of ribavirin for the treatment of respiratory syncytial virus (RSV) associated lower respiratory tract infections. The results showed that ribavirin is effective in treating RSV-LRTI in patients with hematological diseases, and oral ribavirin is associated with increased viral clearance. However, there is a lack of evidence to support its use in lung transplant recipients.
ADVANCES IN THERAPY
(2022)
Article
Immunology
Andrea G. Buchwald, Barney S. Graham, Awa Traore, Fadima Cheick Haidara, Man Chen, Kaitlyn Morabito, Bob C. Lin, Samba O. Sow, Myron M. Levine, Marcela F. Pasetti, Milagritos D. Tapia
Summary: This study showed that maternally transferred RSV antibodies were associated with protection of infants against RSV illnesses, and RSV titers in cord blood could predict the risk of infection in infants.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Shimon Amar, Yonat Shemer Avni, Norm O'Rourke, Tal Michael
Summary: The study examines the incidence rates of infectious diseases after a successful COVID-19 vaccination campaign and the lifting of social restrictions in Israel. The results suggest that the rates of respiratory and gastrointestinal infections have increased, indicating that similar trends could occur in other countries.
Article
Immunology
Zaid Haddadin, Stockton Beveridge, Kailee Fernandez, Danielle A. Rankin, Varvara Probst, Andrew J. Spieker, Tiffanie M. Markus, Laura S. Stewart, William Schaffner, Mary Lou Lindegren, Natasha Halasa
Summary: Respiratory syncytial virus (RSV) is the leading cause of acute respiratory infections (ARIs) in hospitalized children. RSV-positive children were more likely to be hospitalized, require intensive care unit admission, and receive oxygen compared with children positive for other viruses. Higher viral load, White race, younger age, and higher severity score were independently associated with hospitalization in RSV-positive children.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Biotechnology & Applied Microbiology
Fryad Rahman, Camille Libre, Andrew Oleinikov, Sergey Tcherniuk
Summary: The study demonstrates that chloroquine and pyrimethamine can inhibit the replication of human respiratory syncytial virus, and synergistically enhance the anti-replicative effect of ribavirin in cells. Chloroquine can also inhibit hRSV replication in a mouse model, indicating its potential as an interesting compound for the treatment of hRSV infection.
JOURNAL OF GENERAL VIROLOGY
(2021)
Article
Microbiology
Kim Chiok, Swechha M. Pokharel, Indira Mohanty, Lindsay Grace Miller, Shou-Jiang Gao, Arthur L. Haas, Kim C. Tran, Michael N. Teng, Santanu Bose
Summary: Understanding the interaction between RSV and the host is crucial for developing effective interventions. This study identifies the RSV nonstructural protein NS2 as the key component in activating autophagy by modulating the ISGylation of Beclin1.
Article
Microbiology
Kim Chiok, Swechha M. Pokharel, Indira Mohanty, Lindsay Grace Miller, Shou-Jiang Gao, Arthur L. Haas, Kim C. Tran, Michael N. Teng, Santanu Bose
Summary: Paramyxoviruses like RSV are a leading cause of viral pneumonia in infants. This study identified the viral protein NS2 as mediating autophagy induction by RSV, providing a potential target for interventions against RSV.
Article
Medicine, General & Internal
Jocelyn Moyes, Stefano Tempia, Sibongile Walaza, Meredith L. McMorrow, Florette Treurnicht, Nicole Wolter, Anne von Gottberg, Kathleen Kahn, Adam L. Cohen, Halima Dawood, Ebrahim Variava, Cheryl Cohen
Summary: Based on a study in South African children, the burden of RSV-associated illness was estimated, with newborns and infants being the most affected group. Implementing maternal vaccination and monoclonal antibody products for this group can help reduce the disease burden.
Review
Infectious Diseases
Kasama Manothummetha, Thanuthong Mongkolkaew, Punyot Tovichayathamrong, Rabhas Boonyawairote, Tanaporn Meejun, Karan Srisurapanont, Kasidis Phongkhun, Anawin Sanguankeo, Pattama Torvorapanit, Chatphatai Moonla, Rongpong Plongla, Olivia S. Kates, Robin K. Avery, Saman Nematollahi, Nitipong Permpalung
Summary: This study summarized the efficacy of ribavirin in treating respiratory syncytial virus infection in patients with hematologic malignancies and hematopoietic stem cell transplant recipients. The results showed that ribavirin use did not significantly affect all-cause mortality and RSV-associated mortality, but it was associated with lower mortality and progression to lower respiratory tract infection in certain subgroups.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Medicine, General & Internal
Laura L. Hammitt, Ron Dagan, Yuan Yuan, Manuel Baca Cots, Miroslava Bosheva, Shabir A. Madhi, William J. Muller, Heather J. Zar, Dennis Brooks, Amy Grenham, Ulrika Wahlby Hamren, Vaishali S. Mankad, Pin Ren, Therese Takas, Michael E. Abram, Amanda Leach, M. Pamela Griffin, Tonya Villafana
Summary: A single injection of nirsevimab administered before the RSV season protected healthy late-preterm and term infants from medically attended RSV-associated lower respiratory tract infection.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Jason R. Gantenberg, Robertus van Aalst, Nicole Zimmerman, Brendan Limone, Sandra S. Chaves, William V. La Via, Christopher B. Nelson, Christopher Rizzo, David A. Savitz, Andrew R. Zullo
Summary: RSV is a major cause of infant hospitalization in the United States. While preterm infants and those with specific comorbidities are at high risk, 80% of RSV infections occur in term infants without comorbidities. Future prevention efforts should target all infants.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Medicine, General & Internal
Alaa Ahmad, Kingsley Eze, Nicolas Noulin, Veronika Horvathova, Bryan Murray, Mark Baillet, Laura Grey, Julie Mori, Nathalie Adda
Summary: The study demonstrated that EDP-938 was superior to placebo in reducing RSV viral load, total symptom scores, and mucus weight, with a favorable safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Virology
Yishu Wang, Yiling Chen, Ying Lin, Yingqin Quan, Xiaoping Xiao, Renli Zhang
Summary: RSV infection is a major cause of lower respiratory tract disease, with no effective treatments found yet. Recent studies have shown that TRIM family member TRIM22 plays a crucial role in resisting RSV infection. RSV infection induces TRIM22 expression through the activation of JAK-STAT1/2 signaling.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Microbiology
Li Wang, Qihui Zhu, Kunlun Xiang, Yaling Zhang, Baocun Li, Xin Yu, Guang Yang, Chungen Liang, Hongying Yun, Meifang Zhang, Ning Qin, Lu Gao
Summary: A novel triazole-oxadiazole derivative named triazole-1 was discovered as an inhibitor of respiratory syncytial virus (RSV) replication. Triazole-1 showed potent inhibition of both RSV A and B subtypes and specifically targeted RSV transcription, with resistance observed due to a single point mutation in the RSV genome.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)